作者: Jian-Wei Zhang , Tao Qin , Shao-Dong Hong , Jing Zhang , Wen-Feng Fang
DOI: 10.1186/S40880-015-0011-0
关键词:
摘要: An increasing number of targeted drugs have been tested for the treatment nasopharyngeal carcinoma (NPC). However, therapy-related oncogenic mutations not fully evaluated. This study aimed to detect in NPC and determine which therapy might be potentially effective treating NPC. By using SNaPshot assay, a rapid detection method, 19 mutation hotspots 6 oncogenes were examined 70 patients. The associations between clinicopathologic factors analyzed. Among patients, 12 (17.1%) had 5 oncogenes: 7 (10.0%) v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) epidermal growth factor receptor (EGFR) 1 (1.4%) phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) Kirsten rat (KRAS) simultaneous EGFR v-Raf murine B1 (BRAF) mutations. No significant differences observed characteristics. Additionally, these associated with tumor recurrence metastasis. Oncogenic are present efficacy on patients related requires further validation.